GlassScriptPhysician profile
Thomas F Parente
NPI 1093806499
$5,196.49
in general payments reported to CMS, 2019-2025
12 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $293 · 2021: $94.68 · 2022: $2,880 · 2023: $1,496 · 2024: $104 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158 · Travel and Lodging: $489 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.94 |
| Travel and Lodging | $488.80 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,638.54 | 2022-2023 | Venaseal |
| Cvrx, INC. | $337.33 | 2023-2024 | Barostim Neo System |
| Medtronic Vascular, INC. | $244.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $232.66 | 2020-2024 | Farxiga, Brilinta |
| Boston Scientific Corporation | $202.42 | 2020-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Impulse Dynamics (USA) INC. | $137.06 | 2022-2023 | Optimizer |
| Pfizer INC. | $126.75 | 2019-2025 | |
| Amgen INC. | $117.73 | 2019-2024 | Repatha |
| Penumbra, INC. | $73.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.39 | 2023-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $23.43 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.03 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Parente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.